Vitiligo
☆ Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Vitiligo ee faraha ayaa ka dhib badan in la daweeyo marka loo eego meelaha kale. Marka laga reebo in uu yahay mid aan qurux badneyn, vitiligo waa caadi mana la kala qaado. Maqaarka, daaweynta ugu waxtarka badan waa daaweynta sawir-qaadista ama daaweynta laser (excimer) 2-3 jeer toddobaadkii ugu yaraan 1 sano. Haddii aadan marar badan aad u tegi karin isbitaalka sababo dhaqaale dartood ama aad mashquul tahay, waxaad isku dayi kartaa mashiinka sawir-qaadista oo loo oggolaaday isticmaalka guriga.
vitiligo isha
Vitiligo gacanta
References
Vitiligo waa cillad maqaarka ah oo caadi ah oo keenta maqaarka maqaarka cad sababtoo ah luminta melanocytes. Cilmi-baaristii ugu dambeysay waxay muujineysaa inuu yahay cudur difaaca jirka. Iyadoo inta badan loo arko arrin la isku qurxiyo, waxay si qoto dheer u saameyn kartaa fayoobida maskaxda iyo nolol maalmeedka. Sannadkii 2011, khubaradu waxay u kala saareen nooc la yiraahdo segmental vitiligo oo ka duwan kuwa kale.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Bukaannada vitiligo ee firfircoon waxay leeyihiin dhawr ikhtiyaar oo daawaynta ah, sida nidaamka glucocorticoids, daawaynta sawir-qaadista, iyo difaaca habdhiska difaaca. Bukaannada vitiligo deggan waxay ka heli karaan nasasho corticosteroids la mariyo, calcineurin inhibitors-ka jirka la mariyo, daaweynta sawir-qaadista, iyo hababka tallaalka. Horumarkii u dambeeyay ee fahamka hababka hoose ee vitiligo ayaa horseeday horumarinta daawaynta la beegsaday. Waqtigan xaadirka ah, JAK inhibitors waa kuwa ugu rajo-gelinta badan, oo bixiya dulqaad wanaagsan iyo natiijooyin shaqeynaya, in kasta oo khatarta ah in la dhaqaajiyo infekshannada qarsoon iyo saameynaha habaysan ee caadiga ah ee wakiilada kale ee difaaca jirka. Cilmi-baarista socota waxay ujeeddadeedu tahay in la aqoonsado cytokines-yada muhiimka ah ee ku lug leh horumarinta vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Joojinta cytokines-kan waxay muujisay ballan qaadka moodooyinka xayawaanka iyo bukaannada qaarkood. Intaa waxaa dheer, baaritaannada miRNA-based therapeutics iyo adoptive Treg cell therapy ayaa socda.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ma jiro daawo la yaqaan oo loo yaqaan 'vitiligo'. Kuwa maqaarkoodu fudud yahay, kiriimyada qorraxda iyo isqurxinta ayaa ah waxa sida caadiga ah lagula taliyay. Ikhtiyaarada kale ee daawaynta waxaa ka mid noqon kara kiriimyada isteeroid ama daawaynta sawir-qaadista.
○ Daawaynta
#Phototherapy
#Excimer laser
#Tacrolimus ointment